Study highlights need to improve screening and surveillance for Barrett's esophagus

NewsGuard 100/100 Score

A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett's esophagus (BE).

BE is the only identifiable precursor lesion for esophageal adenocarcinoma (EAC), a lethal cancer with increased incidence and mortality rates over the last several decades.

The research, led by faculty at the University of Colorado (CU) Cancer Center, analyzed a large international database of over 20,000 newly diagnosed BE patients in Nordic countries to provide a more accurate look at how many patients have normal endoscopies but still get diagnosed with EAC in a short timeframe.

We found a high proportion of esophageal cancers were found in patients after receiving a normal endoscopy and before the next recommended endoscopy."

Sachin Wani, MD, first author, professor of medicine and director of the Katy O. and Paul M. Rady Esophageal and Gastric Center of Excellence at the CU Cancer Center

The researchers conducted a population-based cohort study and included all patients diagnosed with BE in three Nordic countries: Denmark, Finland and Sweden from 2006 to 2020.

The result showed 25-46% of EACs were categorized as post endoscopy esophageal adenocarcinoma (PEEC). PEEC describes esophageal cancer identified within 1 year of a non-diagnostic upper endoscopy.

"These missed cancers can impact survival rates since catching cancer early is critical for effective treatment," Wani said.

However, Wani and his team say understanding these "missed cancers" can also provide information that can help with developing better interventions.

He adds, "In the past, research was mostly focused on observational studies that were plagued by small sample sizes or selection bias. This means we didn't have a true picture of how current screening practices aren't working for nearly a quarter of EAC patients. With this new research, we're providing more data which is an opportunity to improve the effectiveness of screening and surveillance practices."

Although the reasons are still unclear why these screenings and surveillance strategies are not effective for nearly a quarter of patients, the authors suggest a few ways to improve screenings.

"We suggest providers use the highest quality endoscopy equipment, spend adequate time inspecting the Barrett's segment and ensure that they have the most rigorous sampling protocols in place," Wani says. "At the end of the day, we hope this data can influence providers in clinical practice to improve the quality of care and endoscopies for BE."

The researchers also say future research needs to investigate the role of other diagnostic techniques using biomarker panels to predict prevalent and incident BE-related EAC.

Source:
Journal reference:

Wani, S., et al. (2023) Magnitude and Time-Trends of Postendoscopy Esophageal Adenocarcinoma and Postendoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett’s Esophagus Study. Gastroenterology. doi.org/10.1053/j.gastro.2023.05.044.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ketone supplement boosts efficacy of prostate cancer immunotherapy